Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt No Debt
CRMD's Cash to Debt is ranked higher than
89% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. CRMD: No Debt )
CRMD' s 10-Year Cash to Debt Range
Min: 0.11   Max: No Debt
Current: No Debt

Equity to Asset -0.19
CRMD's Equity to Asset is ranked higher than
50% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. CRMD: -0.19 )
CRMD' s 10-Year Equity to Asset Range
Min: -1.36   Max: -0.19
Current: -0.19

-1.36
-0.19
F-Score: 5
Z-Score: -30.91
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -14155.56
CRMD's Operating margin (%) is ranked higher than
50% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -55.17 vs. CRMD: -14155.56 )
CRMD' s 10-Year Operating margin (%) Range
Min: -245750   Max: -245750
Current: -14155.56

Net-margin (%) -35442.59
CRMD's Net-margin (%) is ranked lower than
51% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -51.98 vs. CRMD: -35442.59 )
CRMD' s 10-Year Net-margin (%) Range
Min: -456650   Max: -456650
Current: -35442.59

ROA (%) -426.89
CRMD's ROA (%) is ranked lower than
51% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -19.98 vs. CRMD: -426.89 )
CRMD' s 10-Year ROA (%) Range
Min: -443.24   Max: -116.99
Current: -426.89

-443.24
-116.99
ROC (Joel Greenblatt) (%) -29175.57
CRMD's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -210.62 vs. CRMD: -29175.57 )
CRMD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -77336.36   Max: -23975.61
Current: -29175.57

-77336.36
-23975.61
» CRMD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

CRMD Guru Trades in Q3 2013

Paul Singer 781,440 sh (unchged)
» More
Q4 2013

CRMD Guru Trades in Q4 2013

Paul Singer 781,440 sh (unchged)
» More
Q1 2014

CRMD Guru Trades in Q1 2014

Paul Singer 781,440 sh (unchged)
» More
Q2 2014

CRMD Guru Trades in Q2 2014

Paul Singer 781,440 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CRMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 616.70
CRMD's P/S is ranked higher than
61% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 19.97 vs. CRMD: 616.70 )
CRMD' s 10-Year P/S Range
Min: 0   Max: 10793.6
Current: 616.7

0
10793.6
EV-to-EBIT -6.72
CRMD's EV-to-EBIT is ranked higher than
79% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CRMD: -6.72 )
CRMD' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -6.72

Current Ratio 6.93
CRMD's Current Ratio is ranked higher than
84% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. CRMD: 6.93 )
CRMD' s 10-Year Current Ratio Range
Min: 0.1   Max: 10.33
Current: 6.93

0.1
10.33
Quick Ratio 6.70
CRMD's Quick Ratio is ranked higher than
85% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.81 vs. CRMD: 6.70 )
CRMD' s 10-Year Quick Ratio Range
Min: 0.1   Max: 10.33
Current: 6.7

0.1
10.33

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) -15.00
CRMD's Earnings Yield (Greenblatt) is ranked higher than
63% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. CRMD: -15.00 )
CRMD' s 10-Year Earnings Yield (Greenblatt) Range
Min: -15.9   Max: 0
Current: -15

-15.9
0
Forward Rate of Return (Yacktman) -57.47
CRMD's Forward Rate of Return (Yacktman) is ranked higher than
61% of the 767 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. CRMD: -57.47 )
CRMD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -57.47

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Cormedix, Inc. was organized as a Delaware corporation on July 28, 2006 under the name Picton Holding Company, Inc. and changed it to CorMedix Inc. on January 18, 2007. The Company develops and seeks to commercialize products for the treatment of cardiac, renal and infectious diseases. Its principal product under development includes CRMD003, an antimicrobial/anticoagulant solution applied in the prevention of catheter related bloodstream infections and maintenance of catheter patency in central venous catheters used for vascular access in hemodialysis patients. Its products also include CRMD004, a pressure sensitive gel that is in pre-clinical Phase.
» More Articles for CRMD

Headlines

Articles On GuruFocus.com
CorMedix Receives Approval From FDA to Initiate a Clinical Trial for Neutrolin in the US Oct 27 2014 
Weekly CFO Buys Highlight: CEP, JNS, CRMD, VAC, TICC Dec 26 2011 
Weekly CFO Buys Highlight: POL, ARAY, ZBB, CRMD, VRX Dec 19 2011 
CORMEDIX INC Reports Operating Results (10-Q) Nov 09 2010 

More From Other Websites
CORMEDIX INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 27 2014
CorMedix Receives Approval From FDA to Initiate a Clinical Trial for Neutrolin in the US Oct 27 2014
CORMEDIX INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 25 2014
CorMedix Announces FDA IND Filing for Neutrolin® in United States Sep 25 2014
CORMEDIX INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 22 2014
Neutrolin Label Expansion Approved for the European Union Sep 22 2014
CORMEDIX INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Amendments to Articles... Sep 16 2014
CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative... Sep 16 2014
CORMEDIX INC. Files SEC form 8-K, Other Events Sep 12 2014
CORMEDIX INC. Financials Aug 22 2014
CORMEDIX INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 14 2014
FDA Accepts CorMedix, Inc. Pivotal Phase 3 Study Protocol Aug 14 2014
CORMEDIX INC. Files SEC form 10-Q, Quarterly Report Aug 14 2014
CORMEDIX INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule... Jul 24 2014
CorMedix, Inc. Granted Extension of NYSE-MKT Listing Jul 24 2014
CORMEDIX INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events,... Jun 26 2014
CorMedix finalizes Phase 3 study protocol with FDA for Neutrolin Jun 23 2014
CorMedix, Inc. Finalizes Pivotal Phase 3 Study Protocol for FDA Jun 23 2014
CORMEDIX INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Jun 17 2014
CORMEDIX INC. Files SEC form 8-K/A, Notice of Delisting or Failure to Satisfy a Continued Listing... May 28 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK